154 related articles for article (PubMed ID: 32358591)
1. 10 years of biosimilars: lessons and trends.
Royzman I; Shah K
Nat Rev Drug Discov; 2020 Jun; 19(6):375. PubMed ID: 32358591
[No Abstract] [Full Text] [Related]
2. The US Biosimilar Market: Stunted Growth and Possible Reforms.
Sarpatwari A; Barenie R; Curfman G; Darrow JJ; Kesselheim AS
Clin Pharmacol Ther; 2019 Jan; 105(1):92-100. PubMed ID: 30415479
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars battle rages on, Amgen fights both sides.
Senior M
Nat Biotechnol; 2013 Apr; 31(4):269-70. PubMed ID: 23563402
[No Abstract] [Full Text] [Related]
4. Patent litigation could make 2017 no 'dancing' matter.
Reinke T
Manag Care; 2016 Dec; 25(12):23-28. PubMed ID: 28121555
[TBL] [Abstract][Full Text] [Related]
5. The comparability conundrum: biosimilars in the United States, Europe and Canada.
Courage N; Parsons A
Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
[TBL] [Abstract][Full Text] [Related]
6. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy.
Bridges SL; White DW; Worthing AB; Gravallese EM; O'Dell JR; Nola K; Kay J; Cohen SB;
Arthritis Rheumatol; 2018 Mar; 70(3):334-344. PubMed ID: 29411547
[No Abstract] [Full Text] [Related]
7. Biosimilars: Key regulatory considerations and similarity assessment tools.
Kirchhoff CF; Wang XM; Conlon HD; Anderson S; Ryan AM; Bose A
Biotechnol Bioeng; 2017 Dec; 114(12):2696-2705. PubMed ID: 28842986
[TBL] [Abstract][Full Text] [Related]
8. Insights of biosimilars through SWOT analysis.
Patel MM; Shah PJ; Patel BM
Expert Opin Biol Ther; 2014 Feb; 14(2):139-44. PubMed ID: 24151903
[No Abstract] [Full Text] [Related]
9. The Biosimilar Pipeline Seams Seem To Be Bursting.
Reinke T
Manag Care; 2017 Mar; 26(3):24-25. PubMed ID: 28510516
[TBL] [Abstract][Full Text] [Related]
10. FDA sets hierarchy for biosimilars evidence.
Ratner M
Nat Biotechnol; 2014 Jul; 32(7):609. PubMed ID: 25004221
[No Abstract] [Full Text] [Related]
11. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
12. Considerations in the early development of biosimilar products.
Li EC; Abbas R; Jacobs IA; Yin D
Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
[TBL] [Abstract][Full Text] [Related]
13. Off-label promotion.
Somberg J
Am J Ther; 2006; 13(5):387. PubMed ID: 16988530
[No Abstract] [Full Text] [Related]
14. First US biosimilar edges towards market.
Senior M
Nat Biotechnol; 2015 Mar; 33(3):222-3. PubMed ID: 25748898
[No Abstract] [Full Text] [Related]
15. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
16. Drug Development. Are trade secrets delaying biosimilars?
Price WN; Rai AK
Science; 2015 Apr; 348(6231):188-9. PubMed ID: 25859034
[No Abstract] [Full Text] [Related]
17. FDA Expectations for Demonstrating Interchangeability.
Chance K
Ther Innov Regul Sci; 2018 May; 52(3):369-373. PubMed ID: 29714562
[TBL] [Abstract][Full Text] [Related]
18. Indiana jumps the biosimilars gun.
Fox JL
Nat Biotechnol; 2014 May; 32(5):406. PubMed ID: 24811502
[No Abstract] [Full Text] [Related]
19. First biosimilar drug approved for sale in the United States.
Hede K
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142444
[No Abstract] [Full Text] [Related]
20. The complexities of biosimilars and the regulatory approval process.
Lucio S
Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
